Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Authors
Keywords
-
Journal
Biomedicines
Volume 9, Issue 8, Pages 985
Publisher
MDPI AG
Online
2021-08-09
DOI
10.3390/biomedicines9080985
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
- (2021) Ismael Valladolid-Acebes et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017
- (2021) Maedeh Amini et al. BMC PUBLIC HEALTH
- Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study
- (2021) Markus Arnold et al. EUROPEAN HEART JOURNAL
- Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors
- (2021) Kwok Leung Ong et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Cholesterol Efflux and Collateral Circulation in Chronic Total Coronary Occlusion: Effect‐Circ Study
- (2021) Seonhwa Lee et al. Journal of the American Heart Association
- Genome-Wide Association Study and Identification of a Protective Missense Variant on Lipoprotein(a) Concentration
- (2021) M. Abdullah Said et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Myeloperoxidase Targets Apolipoprotein A-I for Site-Specific Tyrosine Chlorination in Atherosclerotic Lesions and Generates Dysfunctional High-Density Lipoprotein
- (2021) Zelong Jin et al. CHEMICAL RESEARCH IN TOXICOLOGY
- HDL Containing Apolipoprotein C-III is Associated with Insulin Sensitivity: a Multi-Center Cohort Study
- (2021) Rain Yamamoto et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Ioanna Gouni-Berthold et al. Lancet Diabetes & Endocrinology
- HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases
- (2021) Fabrizia Bonacina et al. Cells
- Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag
- (2021) Bridget M. Kuehn CIRCULATION
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- (2020) Jan Borén et al. EUROPEAN HEART JOURNAL
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease
- (2020) Raul Fernandez-Prado et al. Clinical Kidney Journal
- Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
- (2020) Federica Fogacci et al. Current Atherosclerosis Reports
- Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies
- (2020) Arrigo F. G. Cicero et al. DRUG SAFETY
- Lp(a) concentration, genetic variants, apo(a) isoform size and cellular cholesterol efflux in subjects with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis. The Italian case-control multicentre study on Lp(a)
- (2020) C. Stefanutti et al. Journal of Clinical Lipidology
- Structure–function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk
- (2020) Christina Gkolfinopoulou et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia
- (2020) Laura D’Erasmo et al. EXPERT OPINION ON PHARMACOTHERAPY
- Association of lipoprotein(a) with platelet aggregation and thrombogenicity in patients undergoing percutaneous coronary intervention
- (2020) Pei Zhu et al. PLATELETS
- Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
- (2020) Maciej Banach et al. JAMA Cardiology
- Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
- (2020) C. Michael Gibson et al. AMERICAN HEART JOURNAL
- Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
- (2020) Michael Szarek et al. EUROPEAN HEART JOURNAL
- Higher oxidized high-density lipoprotein to apolipoprotein A-I ratio is associated with high-risk coronary plaque characteristics determined by CT angiography
- (2020) Kazuki Suruga et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Denaturation of human plasma high-density lipoproteins by urea studied by apolipoprotein A-I dissociation
- (2020) Alexander D. Dergunov et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study
- (2020) Ji Eun Jun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia
- (2020) Leopoldo Pérez de Isla et al. EUROPEAN HEART JOURNAL
- High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression?
- (2020) Andrea Bonnin Márquez et al. Biomedicines
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2019) Scott M. Grundy et al. CIRCULATION
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- High-Density Lipoprotein Function and Dysfunction in Health and Disease
- (2019) Scott T. Chiesa et al. CARDIOVASCULAR DRUGS AND THERAPY
- Statin therapy increases lipoprotein(a) levels
- (2019) Sotirios Tsimikas et al. EUROPEAN HEART JOURNAL
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
- (2019) Veronica J Alexander et al. EUROPEAN HEART JOURNAL
- An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients
- (2019) Marcelino Bermudez-Lopez et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group
- (2019) Don P. Wilson et al. Journal of Clinical Lipidology
- Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice
- (2019) Thomas M. Stulnig et al. Current Atherosclerosis Reports
- Current and future role of lipoprotein(a) in preventive cardiology
- (2019) Adam Berman et al. CURRENT OPINION IN CARDIOLOGY
- Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
- (2019) Hayato Tada et al. Journal of Atherosclerosis and Thrombosis
- Lp(a): Addressing a Target for Cardiovascular Disease Prevention
- (2019) Nestor Vasquez et al. Current Cardiology Reports
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical review on triglycerides
- (2019) Ulrich Laufs et al. EUROPEAN HEART JOURNAL
- Statins and increases in Lp(a): an inconvenient truth that needs attention
- (2019) Sotirios Tsimikas et al. EUROPEAN HEART JOURNAL
- Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study
- (2019) Massimiliano Ruscica et al. European Journal of Preventive Cardiology
- APOC3Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular RiskHighlights
- (2018) Anders B. Wulff et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes
- (2018) Priska Stahel et al. CANADIAN JOURNAL OF CARDIOLOGY
- Biological consequences of dysfunctional HDL
- (2018) Angela Prillo et al. CURRENT MEDICINAL CHEMISTRY
- High-density Lipoprotein (HDL) Dysfunction and the Future of HDL
- (2018) Sibel Ertek Current Vascular Pharmacology
- The role of lipoprotein (a) in chronic kidney disease
- (2018) Jemma C. Hopewell et al. JOURNAL OF LIPID RESEARCH
- Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
- (2018) Om P. Ganda et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels
- (2018) Ye-Xuan Cao et al. American Journal of Cardiovascular Drugs
- Severe hypertriglyceridemia is primarily polygenic
- (2018) Jacqueline S. Dron et al. Journal of Clinical Lipidology
- Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis
- (2018) Kathryn J. Moore et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
- (2018) Peter Willeit et al. LANCET
- Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis
- (2018) Haris Riaz et al. European Journal of Preventive Cardiology
- Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study
- (2017) Christian M Madsen et al. EUROPEAN HEART JOURNAL
- Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study
- (2017) Federica Fogacci et al. European Journal of Internal Medicine
- Mast cells in atherosclerotic cardiovascular disease – Activators and actions
- (2017) Petri T. Kovanen et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Lipoprotein(a): A missing culprit in the management of athero-thrombosis?
- (2017) Gianna Ferretti et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin
- (2017) Nuntakorn Thongtang et al. JOURNAL OF LIPID RESEARCH
- Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity
- (2017) Evangelia Zvintzou et al. JOURNAL OF LIPID RESEARCH
- Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease
- (2017) Rai Ajit K. Srivastava MOLECULAR AND CELLULAR BIOCHEMISTRY
- Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity
- (2017) Danish Saleheen et al. NATURE
- Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
- (2017) Shipra Agrawal et al. Nature Reviews Nephrology
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- (2017) A. Michael Lincoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular DiseaseHighlights
- (2016) Eberhard Roeseler et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Changes in mean serum lipids among adults in Germany: results from National Health Surveys 1997-99 and 2008-11
- (2016) Julia Truthmann et al. BMC PUBLIC HEALTH
- Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
- (2016) Florian Kronenberg CARDIOVASCULAR DRUGS AND THERAPY
- Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical Perspective
- (2016) C. Michael Gibson et al. CIRCULATION
- Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in HumansClinical Perspective
- (2016) Fleur M. van der Valk et al. CIRCULATION
- Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
- (2016) Changting Xiao et al. DIABETES
- Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
- (2016) Andres Digenio et al. DIABETES CARE
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Serum amyloid A impairs the antiinflammatory properties of HDL
- (2016) Chang Yeop Han et al. JOURNAL OF CLINICAL INVESTIGATION
- Lipoprotein apheresis to treat elevated lipoprotein (a)
- (2016) Elisa Waldmann et al. JOURNAL OF LIPID RESEARCH
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
- (2016) Børge G. Nordestgaard et al. JOURNAL OF LIPID RESEARCH
- Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?
- (2016) Madhurima Das et al. JOURNAL OF MOLECULAR BIOLOGY
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
- (2016) Nicholas J Viney et al. LANCET
- High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study
- (2016) Anne Langsted et al. Lancet Diabetes & Endocrinology
- Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
- (2016) Rosie Z Yu et al. Molecular Therapy-Nucleic Acids
- The effect of an apolipoprotein A-I–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia
- (2015) G. Kees Hovingh et al. AMERICAN HEART JOURNAL
- Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or PlaceboCLINICAL PERSPECTIVE
- (2015) Samia Mora et al. CIRCULATION
- HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target
- (2015) Anish Bhatt et al. Current Atherosclerosis Reports
- HDL-cholesterol and cardiovascular disease
- (2015) Hasan K. Siddiqi et al. CURRENT OPINION IN CARDIOLOGY
- Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials
- (2015) Susan Kühnast et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Reconstituted high-density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component
- (2015) Eva Herzog et al. JOURNAL OF APPLIED TOXICOLOGY
- Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia
- (2015) R. Vongpromek et al. JOURNAL OF INTERNAL MEDICINE
- Lipoprotein (a) measurements for clinical application
- (2015) Santica M. Marcovina et al. JOURNAL OF LIPID RESEARCH
- Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis
- (2015) Pradeep Natarajan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
- (2015) Gregory G. Schwartz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Apolipoprotein C-III: From Pathophysiology to Pharmacology
- (2015) Giuseppe Danilo Norata et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Infusion of Reconstituted High‐Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
- (2015) Pierluigi Tricoci et al. Journal of the American Heart Association
- Amyloidogenic Propensity of a Natural Variant of Human Apolipoprotein A-I: Stability and Interaction with Ligands
- (2015) Silvana A. Rosú et al. PLoS One
- Structural and Functional Analysis of the ApolipoproteinA-I A164S Variant
- (2015) Jonathan Dalla-Riva et al. PLoS One
- Effects of Native and Myeloperoxidase-Modified Apolipoprotein A-I on Reverse Cholesterol Transport and Atherosclerosis in Mice
- (2014) Bernd Hewing et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group
- (2014) Michel R. Langlois et al. ATHEROSCLEROSIS
- Analysis of common and coding variants with cardiovascular disease in the diabetes heart study
- (2014) Jeremy N Adams et al. Cardiovascular Diabetology
- Mendelian randomization of blood lipids for coronary heart disease
- (2014) Michael V. Holmes et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a) Levels in Familial Hypercholesterolemia
- (2014) Rodrigo Alonso et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Triglycerides and cardiovascular disease
- (2014) Børge G Nordestgaard et al. LANCET
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
- (2014) Anand Rohatgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice
- (2014) Thazha P. Prakash et al. NUCLEIC ACIDS RESEARCH
- Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients
- (2014) D. Keene et al. BMJ-British Medical Journal
- High-Density Lipoprotein Mediated Cellular Cholesterol Efflux in Acute Coronary Syndromes
- (2013) Anouar Hafiane et al. AMERICAN JOURNAL OF CARDIOLOGY
- The Influence of Innate and Adaptive Immune Responses on Atherosclerosis
- (2013) Joseph L. Witztum et al. Annual Review of Pathology-Mechanisms of Disease
- Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux
- (2013) Svetlana Diditchenko et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography
- (2013) Maya S. Safarova et al. ATHEROSCLEROSIS SUPPLEMENTS
- Lipoprotein(a): resurrected by genetics
- (2013) F. Kronenberg et al. JOURNAL OF INTERNAL MEDICINE
- Unraveling the complexities of the HDL lipidome
- (2013) Anatol Kontush et al. JOURNAL OF LIPID RESEARCH
- Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction
- (2013) Pia R. Kamstrup et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
- (2013) Pia R. Kamstrup et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Discovery and refinement of loci associated with lipid levels
- (2013) Cristen J Willer et al. NATURE GENETICS
- Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
- (2013) Georgios Daniil et al. PLoS One
- Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study
- (2013) Pia R Kamstrup et al. Lancet Diabetes & Endocrinology
- The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
- (2013) Robert A Hegele et al. Lancet Diabetes & Endocrinology
- Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous Thrombosis
- (2012) Pia R. Kamstrup et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipid-Related Markers and Cardiovascular Disease Prediction
- (2012) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
- (2012) Suguru Yamamoto et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
- (2012) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events
- (2011) R. S. Rosenson et al. CLINICAL CHEMISTRY
- Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2
- (2011) Alexandra Kadl et al. FREE RADICAL BIOLOGY AND MEDICINE
- Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia
- (2011) Kevin C. Maki et al. Journal of Clinical Lipidology
- Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL
- (2011) Andreas K. Kateifides et al. JOURNAL OF LIPID RESEARCH
- The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils
- (2011) Jitka Petrlova et al. JOURNAL OF LIPID RESEARCH
- Atherosclerosis: current pathogenesis and therapeutic options
- (2011) Christian Weber et al. NATURE MEDICINE
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
- (2011) Amit V. Khera et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I
- (2010) Estelle Nobécourt et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men
- (2010) Min-Jeong Shin et al. ATHEROSCLEROSIS
- Mechanisms of LDL oxidation
- (2010) Hiroshi Yoshida et al. CLINICA CHIMICA ACTA
- Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
- (2010) LANCET
- Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification?
- (2009) R. K. Schindhelm et al. CLINICAL CHEMISTRY
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Modification of High Density Lipoprotein by Myeloperoxidase Generates a Pro-inflammatory Particle
- (2009) Arundhati Undurti et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer
- (2009) Cameron R Stewart et al. NATURE IMMUNOLOGY
- Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome
- (2008) Dick C. Chan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Estimation of LDL-Associated Apolipoprotein B from Measurements of Triglycerides and Total Apolipoprotein B
- (2008) A. M. Baca et al. CLINICAL CHEMISTRY
- Glycation as an atherogenic modification of LDL
- (2008) Nahla Younis et al. CURRENT OPINION IN LIPIDOLOGY
- Dose-Dependent Effect of Rosuvastatin on VLDL-Apolipoprotein C-III Kinetics in the Metabolic Syndrome
- (2008) E. M.M. Ooi et al. DIABETES CARE
- Characterization and properties of preβ-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I
- (2008) Phu T. Duong et al. JOURNAL OF LIPID RESEARCH
- The LDL modification hypothesis of atherogenesis: an update
- (2008) Daniel Steinberg JOURNAL OF LIPID RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search